Antiphage activity of sera during phage therapy in relation to its outcome

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Chanishvili N. Bacteriophages as therapeutic and prophylactic means: summary of the Soviet and post Soviet experiences. Curr. Drug Deliv. 13(3), 309–323 (2016).
  Medline CASGoogle Scholar
• 2 Jerne NK. The presence in normal serum of specific antibody against bacteriophage T4 and its increase during the earliest stages of immunization. J. Immunol. 76(3), 209–216 (1956).
  Medline CASGoogle Scholar
• 3 Capparelli R, Parlato M, Borriello G, Salvatore P, Iannelli D. Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob. Agents Chemther. 51(8), 2765–2773 (2007).
  Medline CASGoogle Scholar
• 4 Singla S, Harjai K, Katare OP, Chhibber S. Encapsulation of bacteriophage in liposome accentuates its entry in to macrophage and shields it from neutralizing antibodies. PLoS ONE 11(4), e0153777 (2016).
  MedlineGoogle Scholar
• 5 Górski A, Międzybrodzki R, Borysowski J et al. Phage as a modulator of immune responses: practical implications for phage therapy. Adv. Virus Res. 83, 41–71 (2012). • Summarizing what is known about phage interactions with the immune system and its significance for phage therapy.
  Medline CASGoogle Scholar
• 6 Sulakvelidze A, Alavidze Z, Morris JG Jr. Bacteriophage therapy. Antimicrob. Agents Chemother. 45(3), 649–659 (2001).
  Medline CASGoogle Scholar
• 7 Ly-Chatain MH. The factors affecting effectiveness of treatment in phages therapy. Front. Microbiol. 5(51), 1–7 (2014). • Discussing what could determine success or failure of phage therapy.
  MedlineGoogle Scholar
• 8 Łusiak-Szelachowska M, Żaczek M, Weber-Dąbrowska B et al. Phage neutralization by sera of patients receiving phage therapy. Viral Immunol. 27(6), 295–304 (2014).
  Medline CASGoogle Scholar
• 9 Kucharewicz-Krukowska A, Ślopek S. Immunogenic effect of bacteriophage in patients subjected to phage therapy. Arch. Immunol. Ther. Exp. 35(5), 553–561 (1987).
  Medline CASGoogle Scholar
• 10 Pagava KI, Gachechiladze KK, Korinteli IA et al. What happens when the child gets bacteriophage per os? Georgian Med. News 196–197, 101–105 (2011).
  MedlineGoogle Scholar
• 11 Pagava KI, Metskhvarishvili GD, Gachechiladze KK, Korinteli IA, Hoyle N, Dzuliashvili MG. Some immunological changes in children with bacterial infections treated with bacteriophages. Georgian Med. News 212, 64–69 (2012).
  MedlineGoogle Scholar
• 12 Międzybrodzki R, Borysowski J, Weber-Dąbrowska B et al. Clinical aspects of phage therapy. Adv. Virus Res. 83, 73–121 (2012). •• Discussing ethical, legal and administrative aspects of phage therapy as well as its results including concrete clinical and laboratory data.
  Medline CASGoogle Scholar
• 13 Ślopek S, Durlakowa I, Weber-Dabrowska B, Kucharewicz-Krukowska A, Dabrowski M, Bisikiewicz R. Results of bacteriophage treatment of suppurative bacterial infections. I. General evaluation of the results. Arch. Immunol. Ther. Exp. 31(3), 267–291 (1983).
  Medline CASGoogle Scholar
• 14 Methods of study of bacterial viruses. In: Bacteriophages. Adams MH (Ed.). Interscience, New York, NY, USA, 443–522 (1959).
  Google Scholar
• 15 Pescovitz MD, Torgerson TR, Ochs HD et al. Effect of rituximab on human in vivo antibody immune responses. J. Allergy Clin. Immunol. 128(6), 1295–1302 (2011).
  Medline CASGoogle Scholar
• 16 Bradley SG, Watson DW. Production of neutralizing antibody by mice injected with actinophage. J. Immunol. 90, 782–787 (1963).
  Medline CASGoogle Scholar
• 17 Stashak PW, Baker PJ, Roberson BS. The serum antibody response to bacteriophage ϕX174 in germ-free and conventionally reared mice. I. Assay of neutralizing antibody by a 50 per cent neutralization method. Immunology 18(2), 295–305 (1970).
  Medline CASGoogle Scholar
• 18 Peacock DB, Jones JV, Gough M. The immune response to ϕX174 in man. I. Primary and secondary antibody production in normal adults. Clin. Exp. Immunol. 13(4), 497–513 (1973).
  Medline CASGoogle Scholar
• 19 Górski A, Ważna E, Weber-Dąbrowska B, Dąbrowska K, Świtała-Jeleń K, Międzybrodzki R. Bacteriophage translocation. FEMS Immunol. Med. Microbiol. 46(3), 313–319 (2006).
  Medline CASGoogle Scholar
• 20 Pincus NB, Reckhow JD, Saleem D, Jammeh ML, Datta SK, Myles IA. Strain specific phage treatment for Staphylococcus aureus infection is influenced by host immunity and site of infection. PLoS ONE 10(4), e0124280 (2015).
  MedlineGoogle Scholar
• 21 Weiner HL, da Cunha AP, Quintana F, Wu H. Oral tolerance. Immunol. Rev. 206, 232–259 (2005).
  MedlineGoogle Scholar
• 22 Faria AM, Weiner HL. Oral tolerance: therapeutic implications for autoimmune diseases. Clin. Dev. Immunol. 13(2–4), 143–157 (2006).
  Medline CASGoogle Scholar
• 23 Majewska J, Beta W, Lecion D et al. Oral application of T4 phage induces weak antibody production in the gut and in the blood. Viruses 7(8), 4783–4799 (2015). • Confirming and extending the data derived from clinical-phage therapy showing very weak antibody responses following oral phage administration.
  Medline CASGoogle Scholar
• 24 Bruttin A, Brüssow H. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob. Agents Chemother. 49(7), 2874–2878 (2005).
  Medline CASGoogle Scholar